Novo Nordisk A/S Common Stock (NVO)
$89.55
1.40 (1.54%)
NVO Stock Quote Delayed 30 Minutes
7 Long-Term Stocks to Buy Before the Bull Market Returns
For massive future returns, consider taking a position in these long-term stocks to buy before the bull market returns.
Louis Navellier's Total Grade
Powered by Portfolio Grader?
Unlock Louis Navellier's
? Stock Report – FREE:
Is ? a BUY?
Powered by Portfolio Grader
A
B
C
D
F
?
Unlock Louis Navellier's
? Stock Report to Find Out – FREE:
Louis Navellier's Total Grade
Powered by Portfolio Grader?
Investing legend Louis Navellier rates ? a "?." Unlock his ? Stock Analysis to find out why – FREE:
Louis Navellier's Total Grade
Powered by Portfolio Grader?
Fundamental Grade
Quantitative Grade
- Sales Growth ?
- Operating Margin Growth ?
- Earnings Growth ?
- Earnings Momentum ?
- Earnings Surprises ?
- Analyst Earnings Revisions ?
- Cash Flow ?
- Return on Equity ?
Previous Close
-
Market Cap
-
PE Ratio
-
EPS
-
Volume (Avg. Vol.)
7.39M
Day's Range
$89.28 - $91.12
52-Week Range
$77.82 - $148.15
Dividend & Yield
$1.03 (1.15%)
NVO Stock Predictions, Articles, and Novo Nordisk A/S Common Stock News
Hold Novo Nordisk Shares for Consistent International Growth
The company's value chain may have been shaken by Covid-19 but it wasn't broken, so Novo Nordisk stock holders should stay invested.
Novo Nordisk Suing Mylan Over Generic Victoza Drug
News of Novo Nordisk suing Mylan is spreading as the two companies prepare for a legal battle over a generic version of Victoza.
Quant Score Keeps Novo Nordisk A/S (NVO) Shares a Buy
As one of the 782 companies in the GICS Health Care sector Novo Nordisk A/S (NYSE:NVO) is a constituent of the 134 company Pharmaceuticals GICS industry group within this sector. NVO has a market value of $102.0 billion which is in the top 10% of its industry group. Portfolio Grader's current ranking for NVO puts it 14 among the 134 companies in this industry group, giving it a well above-average position; in the top quartile of the sector with a ranking of 110 among the 782 companies in the sector, and number 634 in the nearly 5,000 company Portfolio Grader universe.
Novo Nordisk A/S (NVO) a Strong Buy on Top-End Quant Score
Novo Nordisk A/S (NYSE:NVO) is one of the 781 companies in the GICS Health Care sector, and a component of the 134 company Pharmaceuticals GICS industry group within this sector. The market value of NVO is $102.5 billion which places it in the top 10% of its industry group. The stock's current Portfolio Grader score places it 4 among the 134 companies in this industry group, positioning it among the leaders; in the top decile of the sector with a ranking of 46 among the 781 companies in the sector, and number 257 in the nearly 5,000 company Portfolio Grader universe.
High-Level Quant Score Keeps Novo Nordisk A/S (NVO) a Strong Buy
Novo Nordisk A/S (NYSE:NVO) is one of the 781 companies in the GICS Health Care sector, and a component of the 133 company Pharmaceuticals GICS industry group within this sector. NVO's market value is $99.9 billion which falls in the top decile in its industry group. The stock's current Portfolio Grader score places it 4 among the 133 companies in this industry group, putting it in the top decile; among the sector leaders with a ranking of 48 among the 781 companies in the sector, and number 254 in the nearly 5,000 company Portfolio Grader universe.
Novo Nordisk A/S (NVO) a Strong Buy on High-Level Earnings Momentum
Novo Nordisk A/S (NYSE:NVO) ranks in the top 10% of its industry group, Pharmaceuticals, and in the top decile of sector group, Health Care, with a market value of $98.0 billion. From an investment attractiveness viewpoint, NVO is ranked in the top decile of the sector with a ranking of 28 among the 782 companies in the sector; the stock's current Portfolio Grader score places it 2 among the 132 companies in this industry group, putting it in the top decile and number 224 in the 5000 company Portfolio Grader company universe.
High-End Earnings Visibility Analytics Raise Ranking of Novo Nordisk A/S (NVO) to Strong Buy
With a $98.0 billion market value, Novo Nordisk A/S (NYSE:NVO) ranks in the top 10% of its industry group, Pharmaceuticals, and in the top 10% of its sector group, Health Care, in market value. From the viewpoint of investment attractiveness, the stock's current Portfolio Grader score places it 2 among the 133 companies in this industry group, positioning it among the leaders; in the top decile of the sector with a ranking of 29 among the 785 companies in the sector, and number 206 in the nearly 5,000 company Portfolio Grader universe.
